Study of biomarkers for memory loss and dementia
Part of Brain & nervous system, Mental health clinical trials.
This study looks at blood and imaging markers (biomarkers) to better understand and diagnose dementia and mild cognitive impairment. It aims to improve early detection and may help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 50 years old.
- Have a diagnosis of dementia or mild cognitive impairment (MCI) from a doctor.
- Be able and willing to attend study visits and provide data.
- Have a first-degree relative (like a child or sibling) who can give consent on your behalf if you have dementia.
- Have no other major brain conditions, like a past stroke, epilepsy, or brain tumor.
- Be able to have an MRI scan (no pacemaker, metal implants, or severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows older adults with normal memory, mild memory problems, or dementia over a year to see if brain scans and blood tests can predict who will get worse. It may help find early warning signs of Alzheimer's and other dementias.
This study checks how age affects memory and thinking, and compares people with mild memory problems, Alzheimer’s disease types, vascular dementia, and healthy controls. You may help researchers understand brain changes using thinking tests, MRI scans, and blood or spinal fluid tests.
This study follows people with normal thinking, early memory problems, or Alzheimer's disease to understand how the brain changes over time. Researchers will use smell tests, blood work, and memory testing to learn more about these conditions and potentially help future treatments.
This study looks at how common mild cognitive impairment and dementia are in people staying in rehabilitation units for heart, lung, or orthopedic problems. It aims to understand memory and thinking issues that may be overlooked in these settings.
This study looks for “biomarkers” (measurable signs from blood and brain tests) that may help predict who with mild cognitive impairment (MCI) could later develop dementia. Results may help doctors spot risk earlier and better plan care.
This study uses advanced brain scans (MRI and molecular imaging) to get a clearer picture of dementia and mild cognitive impairment (MCI). It aims to learn more about how the brain changes in these conditions, which could help improve diagnosis and treatment.
Hear when a new Dementia Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.